Terms: = Lung cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Treatment
944 results:
1. Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancer treatment (G-DEFINER): study protocol of an observational prospective multicenter study.
Miceli R; Eriksson H; Lo Russo G; Alfieri S; Moksnes Bjaanæs M; Pietrantonio F; De Cecco L; Prelaj A; Proto C; Franzén J; McDonnell D; Berenguer Pina JJ; Beninato T; Mazzeo L; Giannatempo P; Verzoni E; Crown J; Helland Å; Eustace A
Acta Oncol; 2024 Apr; 63():213-219. PubMed ID: 38647024
[TBL] [Abstract] [Full Text] [Related]
2. Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1.
Li J; Ma X; Xu F; Yan Y; Chen W
Pharm Biol; 2024 Dec; 62(1):314-325. PubMed ID: 38571483
[TBL] [Abstract] [Full Text] [Related]
3. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
Bazinet A; Kantarjian H; Bataller A; Pemmaraju N; Borthakur G; Chien K; Alvarado Y; Bose P; Jabbour E; Yilmaz M; DiNardo C; Issa G; Montalban-Bravo G; Short N; Sasaki K; Bull-Linderman D; Daver N; Garcia-Manero G; Ravandi F; Kadia T
Lancet Haematol; 2024 Apr; 11(4):e287-e298. PubMed ID: 38548404
[TBL] [Abstract] [Full Text] [Related]
4. L-Methionine accentuates anti-tumor action of Gefitinib in Gefitinib-resistant lung adenocarcinoma: Role of EGFR/ERK/AKT signaling and histone H3K36me2 alteration.
Pal S; Kabeer SW; Tikoo K
Toxicol Appl Pharmacol; 2024 Apr; 485():116907. PubMed ID: 38521369
[TBL] [Abstract] [Full Text] [Related]
5. Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM.
Watanabe S; Yoshioka H; Sakai H; Hotta K; Takenoyama M; Yamada K; Sugawara S; Takiguchi Y; Hosomi Y; Tomii K; Niho S; Nishio M; Kato T; Takahashi T; Ebi H; Aono M; Yamamoto N; Ohe Y; Nakagawa K
ESMO Open; 2024 Apr; 9(4):102975. PubMed ID: 38520847
[TBL] [Abstract] [Full Text] [Related]
6. Longitudinal Study on Changes of cancer-Related Fatigue in Elderly Patients with Postoperative Chemotherapy for Non-Small Cell lung cancer.
Wang T; Wang Y; Luo Y; Chen H
Ann Ital Chir; 2024; 95(1):22-29. PubMed ID: 38469616
[TBL] [Abstract] [Full Text] [Related]
7. Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis.
Goulart BHL; Mushti SL; Chatterjee S; Larkins E; Mishra-Kalyani PS; Pazdur R; Kluetz PG; Singh H
Lancet Oncol; 2024 Apr; 25(4):455-462. PubMed ID: 38458207
[TBL] [Abstract] [Full Text] [Related]
8. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.
Liu W; Huo G; Chen P
Front Public Health; 2024; 12():1213318. PubMed ID: 38435286
[TBL] [Abstract] [Full Text] [Related]
9. Propyl gallate induces human pulmonary fibroblast cell death through the regulation of Bax and caspase-3.
Park WH
Ann Med; 2024 Dec; 56(1):2319853. PubMed ID: 38373208
[TBL] [Abstract] [Full Text] [Related]
10. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Bataller A; Montalban-Bravo G; Bazinet A; Alvarado Y; Chien K; Venugopal S; Ishizawa J; Hammond D; Swaminathan M; Sasaki K; Issa GC; Short NJ; Masarova L; Daver NG; Kadia TM; Colla S; Qiao W; Huang X; Kanagal-Shamanna R; Hendrickson S; Ravandi F; Jabbour E; Kantarjian H; Garcia-Manero G
Lancet Haematol; 2024 Mar; 11(3):e186-e195. PubMed ID: 38316133
[TBL] [Abstract] [Full Text] [Related]
11. Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram.
Losurdo A; Dipasquale A; Giordano L; Persico P; Lorenzi E; Di Muzio A; Barigazzi C; Korolewicz J; Mehan A; Mohammed O; Scheiner B; Pinato DJ; Santoro A; Simonelli M
Front Immunol; 2024; 15():1323151. PubMed ID: 38298193
[TBL] [Abstract] [Full Text] [Related]
12. Exploring the Potential of Montmorillonite as an Antiproliferative Nanoagent against MDA-MB-231 and MCF-7 Human Breast cancer Cells.
Sabzevari AG; Sabahi H; Nikbakht M; Azizi M; Dianat-Moghadam H; Amoozgar Z
Cells; 2024 Jan; 13(2):. PubMed ID: 38275825
[TBL] [Abstract] [Full Text] [Related]
13. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract] [Full Text] [Related]
14. Diet-induced obesity does not exacerbate cachexia in male mice bearing Lewis-lung carcinoma tumors.
Beaudry AG; Law ML; Gilley-Connor KR; Buley H; Dungan CM; Nascimento CMC; Vichaya EG; Wiggs MP
Am J Physiol Regul Integr Comp Physiol; 2024 Mar; 326(3):R254-R265. PubMed ID: 38252513
[TBL] [Abstract] [Full Text] [Related]
15. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
Cook S; Samuel V; Meyers DE; Stukalin I; Litt I; Sangha R; Morris DG; Heng DYC; Pabani A; Dean M; Navani V
JAMA Netw Open; 2024 Jan; 7(1):e2352302. PubMed ID: 38236598
[TBL] [Abstract] [Full Text] [Related]
16. Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for treatment Selection in Patients with Advanced lung cancer Ineligible for Targeted Therapy.
Mfumbilwa ZA; Simons MJHG; Ramaekers B; Retèl VP; Mankor JM; Groen HJM; Aerts JGJV; Joore M; Wilschut JA; Coupé VMH
Pharmacoeconomics; 2024 Apr; 42(4):419-434. PubMed ID: 38194023
[TBL] [Abstract] [Full Text] [Related]
17. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Lin CC; Garralda E; Schöffski P; Hong DS; Siu LL; Martin M; Maur M; Hui R; Soo RA; Chiu J; Zhang T; Ma B; Kyi C; Tan DS; Cassier PA; Sarantopoulos J; Weickhardt A; Carvajal RD; Spratlin J; Esaki T; Rolland F; Akerley W; Deschler-Baier B; Rispoli L; Samant TS; Chowdhury NR; Gusenleitner D; Kwak EL; Askoxylakis V; De Braud F
Oncoimmunology; 2024; 13(1):2290787. PubMed ID: 38170160
[TBL] [Abstract] [Full Text] [Related]
18. Predicting subsolid pulmonary nodules before percutaneous needle biopsy: a comparison of artificial neural network and biopsy results.
Chuang H; Yun L; Jiang-Ping L; Li L; Liang-Shan L; Ting-Yuan L; Qing-HUa L; He-Nan L; Dong-Yuan L; Xue-Quan H
Clin Radiol; 2024 Mar; 79(3):e453-e461. PubMed ID: 38160104
[TBL] [Abstract] [Full Text] [Related]
19. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
Goto H; Ito S; Kizaki M; Yamaguchi M; Fukuhara N; Kato K; Saito T; Terui Y; Okubo S; Soshin T; Zeng J; Honda H; Badawi M; Ross JA; Izutsu K
Int J Clin Oncol; 2024 Feb; 29(2):232-240. PubMed ID: 38157190
[TBL] [Abstract] [Full Text] [Related]
20. Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer.
Kim K; Kim H; Shin I; Noh SJ; Kim JY; Suh KJ; Kim YN; Lee JY; Cho DY; Kim SH; Kim JH; Lee SH; Choi JK
Sci Rep; 2023 Dec; 13(1):22482. PubMed ID: 38110532
[TBL] [Abstract] [Full Text] [Related]
[Next]
